Actas Dermo-Sifiliográficas

ISSN: 0001-7310

The Official publication of the Spanish Academy of Dermatology and Venereology (AEDV). Actas Dermo-Sifiliográficas, founded in 1909, is the oldest monthly medical journals published in Spain. In the year 2006 has been indexed in the Medlinedatabase, and has become a vehicle for expressing the most current Spanish medicine and modern. All articles are subjected to a rigorous process of revision in pairs, and careful editing for literary and scientific style. Together with the classic Original and Clinical Case Study sections, we also include Reviews, Case Diagnoses, and Book Reviews. Dermo-Sifiliográficas is an essential publication for anyone who needs to be current on all aspects of Spanish and world dermatology.

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), Emerging Sources Citation Index (ESCI)

Abstract
Keywords
Resumen
Palabras clave
Introduction
Methods
Results
Patients older than 65 years
Pediatric patients
Pregnancy, breastfeeding, and wish to become pregnant
Treatment decisions in patients with comorbidities
Obesity
Psoriatic arthritis
Inflammatory bowel disease
Depression
Cancer
Metabolic syndrome
Diabetes
Nonalcoholic fatty liver disease
Cardiovascular disease and risk
Congestive heart failure
Kidney disease
Neurologic disease
Risk management in patients on biologic therapy
Neurotoxicity
Tuberculosis
Viral hepatitis
Hiv infection
Vaccination
Covid-19
Other infectious diseases
Immunogenicity
Surgery
Final conclusions
Funding
Conflicts of interest
Acknowledgments
Bibliography

Consensus Document

DOI: 10.1016/j.ad.2022.01.040

Open Access

Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2—Management of Special Populations, Patients With Comorbid Conditions, and Risk

Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 2 «Manejo de poblaciones especiales, pacientes con comorbilidad y gestión del riesgo»

Download PDF

J.M. Carrascosaa,

, L. Puigb, I.B. Romeroc, L. Salgado-Boqueted, E. del Alcázara, J.J.A. Lencinae, D. Morenof, P. de la Cuevag

a Departamento de Dermatología, Hospital Universitari Germans Trias I Pujol, Badalona, Universitat Autònoma de Barcelona, IGTP, Barcelona, Spain

b Departamento de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

c Departamento de Dermatología, Hospital General Universitario de Alicante-ISABIAL – Universidad Miguel Hernández de Elche, Alicante, Spain

d Departamento de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain

e Servicio de Dermatología, Hospital Universitario Vega Baja, Alicante, Spain

f Departamento de Dermatología, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Sevilla, Spain

g Servicio de Dermatología, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain

Article

This article is available in English

Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2—Management of Special Populations, Patients With Comorbid Conditions, and Risk

J.M. Carrascosa, L. Puig, I.B. Romero, L. Salgado-Boquete, E. del Alcázar, J.J.A. Lencina, D. Moreno, P. de la Cueva

10.1016/j.ad.2022.01.040

Actas Dermosifiliogr. 2022;113:T583-T609

Multimedia

Torus Palatinus

More images.

Publish in

Actas Dermo-Sifiliográficas

Actas Dermo-Sifiliográficas is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.

Indexed in:

Follow us:

Article

Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2—Management of Special Populations, Patients With Comorbid Conditions, and Risk

Subscribe to our newsletter